JP2013528213A - エザチオスタットの錠剤製剤 - Google Patents

エザチオスタットの錠剤製剤 Download PDF

Info

Publication number
JP2013528213A
JP2013528213A JP2013514169A JP2013514169A JP2013528213A JP 2013528213 A JP2013528213 A JP 2013528213A JP 2013514169 A JP2013514169 A JP 2013514169A JP 2013514169 A JP2013514169 A JP 2013514169A JP 2013528213 A JP2013528213 A JP 2013528213A
Authority
JP
Japan
Prior art keywords
tablet
ezatiostat hydrochloride
pharmaceutically acceptable
weight percent
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013514169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528213A5 (enExample
Inventor
ロバート・ティ・ラム
ステファン・ディ・ペアレント
チアオ・チュンション
スティーブン・アール・ショウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terrapin Technologies Inc
Original Assignee
Terrapin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terrapin Technologies Inc filed Critical Terrapin Technologies Inc
Publication of JP2013528213A publication Critical patent/JP2013528213A/ja
Publication of JP2013528213A5 publication Critical patent/JP2013528213A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013514169A 2010-06-07 2011-03-29 エザチオスタットの錠剤製剤 Withdrawn JP2013528213A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35237710P 2010-06-07 2010-06-07
US61/352,377 2010-06-07
PCT/US2011/030376 WO2011156045A2 (en) 2010-06-07 2011-03-29 Tablet formulation of ezatiostat

Publications (2)

Publication Number Publication Date
JP2013528213A true JP2013528213A (ja) 2013-07-08
JP2013528213A5 JP2013528213A5 (enExample) 2014-05-15

Family

ID=42829329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013514169A Withdrawn JP2013528213A (ja) 2010-06-07 2011-03-29 エザチオスタットの錠剤製剤

Country Status (8)

Country Link
US (2) US20110300215A1 (enExample)
EP (1) EP2576591A2 (enExample)
JP (1) JP2013528213A (enExample)
CN (1) CN102917694A (enExample)
AR (1) AR080895A1 (enExample)
CA (1) CA2797458A1 (enExample)
TW (1) TW201143761A (enExample)
WO (1) WO2011156045A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151051A1 (en) * 2011-05-03 2012-11-08 Telik, Inc. Excipient compatibility with ezatiostat
US20130035389A1 (en) 2011-08-05 2013-02-07 Telik, Inc. Methods for treating myelodysplastic syndrome with ezatiostat
US10156885B2 (en) 2014-04-07 2018-12-18 Avago Technologies International Sales Pte. Limited Network energy consumption reduction
WO2016117927A1 (ko) 2015-01-20 2016-07-28 주식회사 한림포스텍 무선 전력 전송 장치 및 이의 전송 전력 제어 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5114003A (en) * 1991-03-28 1992-05-19 E. I. Du Pont De Nemours And Company Tablet vial with desiccant in bottom
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US6627732B1 (en) * 1998-04-16 2003-09-30 Teijin Limited Glutathione derivatives and their dosage forms
WO2002088664A2 (en) * 2001-04-26 2002-11-07 Bristol-Myers Squibb Company Control of compactability through crystallization
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2005065639A2 (en) 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
CN101133020A (zh) * 2004-12-03 2008-02-27 特瓦制药工业有限公司 依泽替米贝多晶型
HRP20090128T3 (hr) * 2005-01-06 2009-04-30 Telik Inc. Tripeptid i tetrapeptid tioeteri
EP1880722B1 (en) 2006-07-19 2010-03-17 Tabuk Pharmaceutical Manufacturing Co. Pharmaceutical compositions of ciprofloxacin
EP2125715A2 (en) * 2007-01-24 2009-12-02 Krka Process for the preparation of ezetimibe and derivatives thereof
EP2114380A1 (en) 2007-01-25 2009-11-11 Panacea Biotec Ltd. Modified release pharmaceutical composition and a process of making the same
MX2010001711A (es) 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos

Also Published As

Publication number Publication date
WO2011156045A2 (en) 2011-12-15
US20120021054A1 (en) 2012-01-26
CA2797458A1 (en) 2011-12-15
US8361971B2 (en) 2013-01-29
EP2576591A2 (en) 2013-04-10
TW201143761A (en) 2011-12-16
US20110300215A1 (en) 2011-12-08
AR080895A1 (es) 2012-05-16
CN102917694A (zh) 2013-02-06
WO2011156045A3 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
JP6034789B2 (ja) 結晶性ナロキソール−ｐｅｇ接合体
AU2012252380B2 (en) Polymorph of Linagliptin benzoate
Santos et al. Polymorphism: an evaluation of the potential risk to the quality of drug products from the Farmácia Popular Rede Própria
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
KR101880255B1 (ko) 리팍시민 및 아미노산을 포함하는 약학적 조성물, 이의 제조방법 및 용도
AU2019297421B2 (en) Polymorphic forms of RAD 1901-2HCL
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
Salazar-Rojas et al. Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate
AU2023246775A1 (en) Crystalline hydrobromide salt of 5-meo-dmt
JP2017193561A (ja) ３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態
JP2013528213A (ja) エザチオスタットの錠剤製剤
US20110301088A1 (en) Crystalline ezatiostat hydrochloride ansolvate
UA113302C2 (xx) Кристалічний поліморф 1-(3-трет-бутил-1-п-толіл-1h-піразол-5-іл)-3-(5-фтор-2-(1-(2-гідроксіетил)-1н-індазол-5-ілокси)бензил)сечовини гідрохлориду
TW202434570A (zh) 嘧啶三唑化合物之固體及共晶體形式
JP2022101588A (ja) マリゾミブのモルフィック形態およびその使用
SI9300150A (en) Endo-2,3-dihydro-n-(8-methyl-8-azabicyclo(3.2.1) okt-3-yl)-2-oxo-1h- benzimidazol-1-carboxamid hydrochlorid monohydrate and endo-3-ethyl- 2,3-dihydro-n-(8-methyl-8-azabicyclo-(3.2.1) okt-3-yl)-2-oxo-1h- benzimidazole-1-carboxamid hydrochlorid monohydr
US20220298158A1 (en) Polymorph of venetoclax and method for preparing the polymorph
EA041771B1 (ru) Гидратированная аморфная форма 4-(2,4-дихлор-5-метоксианилино)-6-метокси-7-[3-(4-метилпиперазин-1-ил)пропокси]хинолин-3-карбонитрила (варианты), способ её получения и применение для лечения онкологических заболеваний
Navnitbhai Study on Effect of Processing Parameters on Phase Inversion of Sibutramine Hcl
EA046472B1 (ru) Твердотельные формы (s)-2-(((s)-6,8-дифтор-1,2,3,4-тетрагидронафталин-2-ил)амино)-n-(1-(2-метил-1-(неопентиламино)пропан-2-ил)-1h-имидазол-4-ил)пентанамида и их применения
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140327

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150109